HilleVax, Inc. (NASDAQ:HLVX) Short Interest Update

HilleVax, Inc. (NASDAQ:HLVX) saw a large growth in short interest during the month of December. As of December 15th, there was short interest totalling 1,300,000 shares, a growth of 7.4% from the November 30th total of 1,210,000 shares. Currently, 5.9% of the company’s shares are sold short. Based on an average daily volume of 195,800 shares, the short-interest ratio is presently 6.6 days.

Institutional Trading of HilleVax

Several hedge funds and other institutional investors have recently added to or reduced their stakes in HLVX. Frazier Life Sciences Management L.P. boosted its position in shares of HilleVax by 8.5% in the second quarter. Frazier Life Sciences Management L.P. now owns 10,617,062 shares of the company’s stock worth $153,523,000 after acquiring an additional 835,590 shares during the last quarter. Braidwell LP purchased a new position in HilleVax during the third quarter worth approximately $1,873,000. Point72 Asset Management L.P. acquired a new position in shares of HilleVax in the 2nd quarter valued at $6,960,000. Trium Capital LLP purchased a new stake in shares of HilleVax during the 3rd quarter valued at $798,000. Finally, Ensign Peak Advisors Inc grew its stake in shares of HilleVax by 164.8% during the 2nd quarter. Ensign Peak Advisors Inc now owns 311,784 shares of the company’s stock valued at $4,508,000 after buying an additional 194,038 shares during the period. Hedge funds and other institutional investors own 86.42% of the company’s stock.

HilleVax Stock Performance

NASDAQ HLVX traded up $0.09 during mid-day trading on Wednesday, reaching $2.07. 615,336 shares of the stock were exchanged, compared to its average volume of 230,903. The stock has a market capitalization of $103.11 million, a PE ratio of -0.67 and a beta of 0.81. HilleVax has a 1-year low of $1.55 and a 1-year high of $20.22. The business’s fifty day simple moving average is $1.90 and its 200 day simple moving average is $3.09.

HilleVax (NASDAQ:HLVX) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.10). On average, analysts anticipate that HilleVax will post -2.64 EPS for the current year.

HilleVax Company Profile

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.